On May 28, Agilent Technologies surged 16.27% in regular trading, reaching $133.65 per share with trading volume of $74.9 million, as a strong fiscal Q2 earnings report and upward guidance revision fueled investor optimism.

Agilent reported fiscal Q2 adjusted EPS of $1.49, beating the consensus estimate of $1.41 by 5.67% and representing a 13.74% year-over-year increase. Revenue came in at $1.835 billion versus the expected $1.799 billion, up approximately 10.2% year-over-year, with all end markets delivering strong performance and operating margins hitting a record high. The company raised its full-year adjusted EPS guidance to $6.00–$6.10, up from the prior range of $5.90–$6.04, signaling management confidence in sustained demand for its laboratory research and diagnostic instruments.

Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $153 price target, later raised to $155. Management highlighted GLP-1 drug momentum driving approximately 20% growth year-to-date, while US pharmaceutical reshoring is expected to present a $1 billion opportunity for analytical instruments. The company also launched OpenLab Sync and became the first integrator on the USP MethodConnect platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)